Brief: TOT Biopharm International Got Marketing Approval For Megestrol Acetate Oral Suspension From NMPA
13/05/2021 05:14
May 13 (Reuters) - TOT BIOPHARM International Co Ltd
1875.HK :
* MARKETING APPROVAL FOR MEGESTROL ACETATE ORAL SUSPENSION
(TOM218) OBTAINED FROM NMPA
Source text for Eikon: urn:newsml:reuters.com:*:nHKS31Z0dw
Further company coverage: 1875.HK
(Reuters.briefs@thomsonreuters.com)
Recent news on BioDlink International
See all newsCorrected: China's BioDlink International HY revenue falls (September 29)
Brief: Biodlink International To Deliver Ten Batches Of Monoclonal Antibody Intermediates To Wuxi Biologics
Brief: Biodlink International Says Shan Fu Resigns As Executive Director And Chairperson
Brief: BioDlink International Says WuXi XDC Cayman To Make Conditional Cash Offer For All Co Shares
Brief: HKEX Says Trading In Shares Of Biodlink International Will Be Halted At Dec 29